Search for content, post, videos

Category

Biotech Business

pelago
0 COMMENT
150 Views
Pelago Bioscience and CBCS collaborates

Pelago Bioscience and Chemical Biology Consortium Sweden (CBCS), the chemical biology facility at Karolinska Institutet and SciLifeLab (Science for Life Laboratory) will collaborate to develop high throughput automated CETSA-based Target Engagement Assays for multiple targets. The collaboration is based on expanding Pelago’s CETSA technology capabilities and will enable screening of…

agreement
0 COMMENT
152 Views
Pelago collaborates with Sygnature

UK’s Sygnature Discovery will collaborate with Swedish biotech company Pelago Bioscience to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA) method. Pelago’s CETSA method enables measurements to be made within cellular systems. For the first time researchers can now measure directly how a compound interacts with…

betagenon
0 COMMENT
141 Views
Betagenon receives EUR 1.8 million

The Umeå based company Betagenon receives €1,8 million, from EU’s sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and associated cardiovascular disease. “An increase in calorie intake combined with an inactive life style has brought about a global epidemic…

kristina_runeberg
0 COMMENT
37 Views
Takara Bio launches human iPSC-derived beta cells

Takara Bio Europe AB, which specializes in human induced pluripotent stem cell (hiPSC)-derived cells and medias for scale-up and differentiation, has expanded its offering of tools for drug discovery and disease modeling. Takara Bio announces the launch of fully differentiated, Cellartis hiPS beta cells for research use. These cells are…

peter_rosholm_albumedix
0 COMMENT
41 Views
Albumedix enters new agreements

Albumedix and Hebei Changshan Biochem Pharma announced before the summer that they have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing. The agreement will see Albumedix’s recombinant albumin based half-life extension platform used for the development and later commercialization…

lars hedby idogen
0 COMMENT
21 Views
Idogen collaborates with the University of Oxford

Idogen has initiated a collaboration with Richard Williams’ research group at the Kennedy Institute of Rheumatology at the University of Oxford. Using a research model of rheumatoid arthritis, the collaboration will investigate the treatment effect of follow-up molecules to Zebularine, which Idogen identified and filed for patent protection for this Spring. The company…

anders rylander biovica
0 COMMENT
34 Views
Biovica acquires cSens

Biovica has acquired cSens, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum ™, which is currently included in clinical studies with leading cancer…

targovax board of directors
0 COMMENT
24 Views
Targovax’s interim report Q1 2016

Targovax’s interim report of the first quarter 2016 shows promising data and the funding situation is satisfactory comments the company’s CEO. Targovax has dring the first quarter showed promising data for interim survival analysis of a first cohort of the ongoing open label, phase I/II of TG01/GM-CSF and gemcitabine in…

diamyd vial
0 COMMENT
29 Views
Diamyd increases investment in Cellaviva

Diamyd Medical has announced that the company has increased its investment in the associated company Cellaviva with an additional SEK 1.3 million. The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders. The convertible loan will, among others, be used to finance…

olink proseek
0 COMMENT
23 Views
Olink reorganizes

Swedish Olink has gone through a formal reorganization, and as of April 1, 2016 it is operating as two separate companies, each with its own distinct focus area. Olink Proteomics will continue to expand and develop the Proseek Multiplex product line for targeted human protein biomarker discovery. Olink Bioscience will…

agreement
0 COMMENT
29 Views
BioSilta acquires worldwide rights to CyDisCo

BioSilta, a privately-held company that utilizes its EnBase technology platform to develop reagent-based EnPresso bacterial and yeast expression culture systems, has acquired a license to worldwide exclusive rights to CyDisCo (Cytoplasmic Disulphide bond formation in E. coli) protein production technology from the University of Oulu. This license agreement will enable BioSilta…